Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 12/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 12/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3032323 | 0.86 | S1PR1 (0.30) | S1PR1 | |
| SCHEMBL3296989 | 0.83 | TP53 (0.35) | TP53KEAP1NFE2L2SMN1; SMN2ALDH1A1 | |
| SCHEMBL3301530 | 0.82 | TP53 (0.38) | TP53KEAP1NFE2L2SMN1; SMN2ALDH1A1 | |
| SCHEMBL13409276 | 0.81 | ROCK2 (0.30) | — | |
| SCHEMBL13391061 | 0.80 | KEAP1 (0.44) | KEAP1NFE2L2ALDH1A1L3MBTL1S1PR1 | |
| SCHEMBL3298487 | 0.79 | ALDH1A1 (0.39) | KEAP1NFE2L2ALDH1A1L3MBTL1S1PR1 | |
| SCHEMBL13391139 | 0.79 | L3MBTL1 (0.38) | KEAP1NFE2L2SMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL3302803 | 0.79 | KEAP1 (0.37) | KEAP1NFE2L2SMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL3299974 | 0.78 | ROCK2 (0.54) | TP53KEAP1NFE2L2SMN1; SMN2ALDH1A1 | |
| SCHEMBL3302235 | 0.78 | KEAP1 (0.36) | KEAP1NFE2L2SMN1; SMN2ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121600-B1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INT (DE) | 2012-07-18 | — | — | EP | disclosed |
| US-20100093703-A1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
| US-20100093703-A1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093703-A1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | PYGL, PYGM, G6PC1 | TP53 3881/4885KEAP1 1594/4885NFE2L2 4427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.